We partner with visionary, research-driven teams with the goal of improving lives through advancing therapeutics.
Coastal Life Science ("CLS") was established in 2017 as a venture capital arm focused on biopharma and biotechnology. The investment team's professionals are located in Shenzhen, Shanghai and Hong Kong. CLS collaborates with teams of distinguished expatriate Chinese returnees and some of the best known hospitals in first-tier Chinese cities to translate promising scientific research into innovative solutions and treatments in areas of unmet need, with a global perspective and a focus on affordable therapy for the general public in China.
0755-8202 9222
38/F, Noble Financial Centre, Futian District, Shenzhen
Biopharma
Biopharma
CLS works with teams with strong research capabilities focusing on the discovery and development of monoclonal antibodies, peptide therapeutics, molecularly targeted therapy and preventive and therapeutic vaccines. CLS has a (noncontrolling) interest in Shanghai Junshi Biosciences, which has a strong pipeline of monoclonal antibodies drugs and is currently traded on China's NEEQ.
Biotechnology
Biotechnology
CLS invests in start-ups focusing on stem cell therapy and genetic testing and engineering. It has a (noncontrolling) interest in Beijing Ruige Taibo Biotech Limited, which conducts clinical translational research of stem cell therapies, and a (noncontrolling) interest in Genecast, a genetics testing start-up based in Beijing.
Others
Others
CLS has a (noncontrolling) interest in a triple A-rated private hospital and two nationwide private hospital chains. In addition, it is collaborating with one of Shanghai's largest hospitals on AI-powered medical imaging diagnostics, with the goal of providing radiologists the tools they need to enhance efficiency and accuracy.